PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer

K. Muro; H. Uetake; K. Tsuchihara; K. Shitara; K. Yamazaki; M. Ota; E. Oki; T. Sato; T. Naitoh; Y. Komatsu; T. Kato; K. Yamanaka; I. Mori; J. Soeda; M. Hihara; T. Yamanaka; K. Akagi; A. Ochiai; T. Yoshino

doi:10.1093/annonc/mdz155.033

PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer

K. Muro, H. Uetake, K. Tsuchihara, K. Shitara, K. Yamazaki, M. Ota, E. Oki, T. Sato, T. Naitoh, Y. Komatsu, T. Kato, K. Yamanaka, I. Mori, J. Soeda, M. Hihara, T. Yamanaka, K. Akagi, A. Ochiai, T. Yoshino

MED - Medical Sciences

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	iv10
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	30
DOIs	https://doi.org/10.1093/annonc/mdz155.033
Publication status	Published - 2019 Jul 1

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdz155.033

Cite this

Muro, K., Uetake, H., Tsuchihara, K., Shitara, K., Yamazaki, K., Ota, M., Oki, E., Sato, T., Naitoh, T., Komatsu, Y., Kato, T., Yamanaka, K., Mori, I., Soeda, J., Hihara, M., Yamanaka, T., Akagi, K., Ochiai, A., & Yoshino, T. (2019). PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 30, iv10. https://doi.org/10.1093/annonc/mdz155.033

PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. / Muro, K.; Uetake, H.; Tsuchihara, K. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, 01.07.2019, p. iv10.

Research output: Contribution to journal › Article › peer-review

Muro, K, Uetake, H, Tsuchihara, K, Shitara, K, Yamazaki, K, Ota, M, Oki, E, Sato, T, Naitoh, T, Komatsu, Y, Kato, T, Yamanaka, K, Mori, I, Soeda, J, Hihara, M, Yamanaka, T, Akagi, K, Ochiai, A & Yoshino, T 2019, 'PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 30, pp. iv10. https://doi.org/10.1093/annonc/mdz155.033

Muro K, Uetake H, Tsuchihara K, Shitara K, Yamazaki K, Ota M et al. PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Jul 1;30:iv10. doi: 10.1093/annonc/mdz155.033

@article{d691e26d95ad44ce82222f06d262d338,

title = "PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer",

author = "K. Muro and H. Uetake and K. Tsuchihara and K. Shitara and K. Yamazaki and M. Ota and E. Oki and T. Sato and T. Naitoh and Y. Komatsu and T. Kato and K. Yamanaka and I. Mori and J. Soeda and M. Hihara and T. Yamanaka and K. Akagi and A. Ochiai and T. Yoshino",

year = "2019",

month = jul,

day = "1",

doi = "10.1093/annonc/mdz155.033",

language = "English",

volume = "30",

pages = "iv10",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - PARADIGM study

T2 - A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer

AU - Muro, K.

AU - Uetake, H.

AU - Tsuchihara, K.

AU - Shitara, K.

AU - Yamazaki, K.

AU - Ota, M.

AU - Oki, E.

AU - Sato, T.

AU - Naitoh, T.

AU - Komatsu, Y.

AU - Kato, T.

AU - Yamanaka, K.

AU - Mori, I.

AU - Soeda, J.

AU - Hihara, M.

AU - Yamanaka, T.

AU - Akagi, K.

AU - Ochiai, A.

AU - Yoshino, T.

PY - 2019/7/1

Y1 - 2019/7/1

UR - http://www.scopus.com/inward/record.url?scp=85079794788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079794788&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz155.033

DO - 10.1093/annonc/mdz155.033

M3 - Article

C2 - 32084926

SN - 0923-7534

VL - 30

SP - iv10

JO - Annals of Oncology

JF - Annals of Oncology

ER -

PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this